3.50
Briacell Therapeutics Corp stock is traded at $3.50, with a volume of 357.04K.
It is up +7.36% in the last 24 hours and up +13.64% over the past month.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
See More
Previous Close:
$3.26
Open:
$3.36
24h Volume:
357.04K
Relative Volume:
1.81
Market Cap:
$30.45M
Revenue:
-
Net Income/Loss:
$-30.98M
P/E Ratio:
-0.2866
EPS:
-12.2116
Net Cash Flow:
$-31.84M
1W Performance:
+12.90%
1M Performance:
+13.64%
6M Performance:
-51.19%
1Y Performance:
+20.27%
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BCTX
Briacell Therapeutics Corp
|
3.50 | 28.19M | 0 | -30.98M | -31.84M | -12.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
Why did BCTX stock surge 50% today? - MSN
Number of shareholders of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Price to book forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Price to sales forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Enterprise value to EBIT forward of BriaCell Therapeutics Corp. – BOATS:BCTXZ - TradingView
Price to earnings forward of BriaCell Therapeutics Corp – TSX:BCT - TradingView
Price to sales forward of BriaCell Therapeutics Corp. – BOATS:BCTXZ - TradingView
Price to earnings forward of BriaCell Therapeutics Corp. – BOATS:BCTXZ - TradingView
Enterprise value to revenue forward of BriaCell Therapeutics Corp. – NASDAQ:BCTX - TradingView
Price to sales forward of BriaCell Therapeutics Corp. – NASDAQ:BCTX - TradingView
Enterprise value to EBITDA forward of BriaCell Therapeutics Corp. – NASDAQ:BCTX - TradingView
BriaCell subsidiary BriaPro reports $1.32M assets, $299,950 cash after sCD80 license acquisition - TradingView
BriaCell (NASDAQ: BCTX) unit BriaPro posts loss and acquires sCD80 license - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
What Does BriaCell's Latest Offering Mean for Shareholders - Kavout | AI
BriaCell Therapeutics Corp Actuals & Estimates (TSX:BCT) - TradingView
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT - marketscreener.com
BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development - GuruFocus
BriaCell plans microneedle delivery scale-up for breast cancer drug - Stock Titan
Beyond the Syringe: How Microneedles Could Redefine Cancer Care - BriefGlance
Briacell Therapeutics Corp (BCTX) Institutional Confidence - TradingKey
Briacell Therapeutics Corp (BCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Briacell Therapeutics Corp (BCTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Briacell Therapeutics Corp (BCTXW) Institutional Confidence - TradingKey
Briacell Therapeutics Corp (BCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Briacell Therapeutics Corp (BCTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Briacell Therapeutics Corp (BCTXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Briacell Therapeutics Corp (BCTXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Briacell Therapeutics Corp (BCTXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Briacell Therapeutics Corp (BCTXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Briacell Therapeutics Corp (BCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Briacell Therapeutics Corp (BCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Briacell Therapeutics Corp (BCTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Briacell Therapeutics Corp (BCTXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Briacell Therapeutics Corp (BCTXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Briacell Therapeutics Corp - TradingKey
Why Briacell Therapeutics Corp stock is rising today - Wealth Awesome
Why Briacell Therapeutics Corp stock is plummeting today - Wealth Awesome
BCTXZ SEC FilingsBriacell Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
BCTX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares Amid Revenue AbsenceROE Trend Analysis - newsline.com
BriaCell (NASDAQ: BCTX) ramps cancer trials but flags going concern risk - Stock Titan
BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026 - marketscreener.com
BriaCell receives FDA clearance for breast cancer therapy trial - Investing.com
BriaCell Therapeutics Completes Equity Offering to Fund Operations - The Globe and Mail
Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer - Investing News Network
BriaCell (NASDAQ: BCTX) completes $4.71M best efforts common share sale - Stock Titan
BriaCell Therapeutics Prices $4.71 Million Share Offering at $3.25; ThinkEquity as Placement Agent - TradingView
Beyond the Lab: Top-Tier Clinical Validation in Biotech Investing - Investing News Network
BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering - Moomoo
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):